Amidst increasing concerns of the Delta variant spreading more infections globally, RedHill Biopharma, an Israeli pharmaceutical company has claimed that it is just weeks away from making a major breakthrough in its oral drug that will help get COVID-19 patients off oxygen support more quickly.
Opaganib- RedHill’s oral drug candidate has until now, shown promising signs in treating patients with severe breathing-related symptoms caused by the coronavirus. As it stands, opaganib is an inhibitor that acts on both the cause and effect of COVID-19. It has a dual mechanism of action as it is anti-inflammatory and antiviral, which the company hails as a big differentiator with other treatments.
Speaking to The Algemeiner, Guy Goldberg, Chief Business Officer at RedHill Biopharma said, “Delta variants are scaring everyone, rightfully so, and more and more people are nervous about what’s going to happen. Vaccines are being less and less effective than we thought as the rate of infection is becoming higher and higher. It is not just the question of people who are unvaccinated. This is an emerging story and one that threatens to bring the whole world back to square one. The need for therapeutics is as strong now as it ever has been during the pandemic, and there is not enough innovation out there.”
If authorized, the oral pill will be a lot easier to prepare, administer and distribute than injectable treatments like Remdesivir.